Caution: For Laboratory Use. A product for research purposes only.

Bioluminescent Glucose Luciferin

DESCRIPTION:

Glucose is a major source of energy for most living organisms, and its aberrant uptake is linked to many pathological conditions. Bioluminescent Glucose Luciferin (BiGLuc) is a recently developed bioluminescent glucose-uptake probe for real-time, non-invasive longitudinal imaging of glucose absorption both in *vitro* and *in vivo*. The sensitivity of BiGLuc probe is comparable with that of commonly used ¹⁸F-FDG-positron-emissiontomography tracers. The probe was validated as a tool for the identification of new glucose transport inhibitors, enabling a wide range of applications in the fields of metabolism and drug development.

> 2.0 - 1.5

> > 0.5

E1.0 x10⁵





SwissLumix Sarl EPFL Technology Park, Batiment C Lausanne, Switzerland T: +41 78 857 1660 www.swisslumix.com

(A) Representative image of tumor injected bearing mouse BiGLuc imaging probe. The tumor cells were transduced with Luciferase expressing construct.

(B) Representative image transgenic mice expressing luciferase under beta-actin promoter (FVB+luc).

In both (A) and (B) the amount of light represents the level of glucose uptake



Caution: For Laboratory Use. A product for research purposes only.

Bioluminescent Glucose Luciferin

CONTENTS:

Each "BiGluc" kit contains 1mL of **Solution A** and 2 ml of **Solution B** required for 10 mouse injections.

STORAGE:

Upon receipt, the kit should be stored at -80 °C. When stored and handled properly, the kit compounds are stable for six months.

PROTOCOL:



- 1) Inject 100 μL of **Solution A** intravenously in luciferase expressing animals. Wait for 12-24 hrs.
- 2) Inject 200 µL of **Solution B** intraperitonealy and immediately image the animals continuously for 30-60min with 2 min intervals.
- 3) The data for each animal should be calculated as the area under the curve over 30 60 min.

REFERENCES:

1) Maric T. et al. **Bioluminescent-based imaging and quantification of glucose uptake in vivo.** <u>Nat Methods.</u> 2019 May 13. doi: 10.1038/s41592-019-0421-z

SwissLumix Sarl EPFL Technology Park, Batiment C Lausanne, Switzerland T: +41 78 857 1660 www.swisslumix.com

